Since sorafenib remains the first-line treatment for HCC, and regorafenib is the second line drug for patients who progress with sorafenib, we tested these drugs in the AKT/c-MET murine HCC model (Figure 1A). This evidence concerns the gene MET and hepatocellular carcinoma.